Xiao-dong D. Jiao

Baoshan Branch
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Targeted therapy in advanced BRAF-mutated colorectal cancer: systematic review and network meta-analysis.

Targeted therapy in advanced BRAF-mutated colorectal cancer: systematic review and network meta-analysis.

Journal: BMJ (Clinical research ed.)

Published: December 08, 2025

The Association Between Tumor Burden and the Efficacy of Immunotherapy Among Patients With Non-small Cell Lung Cancer.

The Association Between Tumor Burden and the Efficacy of Immunotherapy Among Patients With Non-small Cell Lung Cancer.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: February 12, 2025

Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial.

Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial.

Journal: Signal transduction and targeted therapy

Published: January 12, 2025

Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial.

Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial.

Journal: Nature communications

Published: January 05, 2025

Impact of molecular tumor board on clinical outcomes in patients with refractory solid tumors: a real-world study.

Impact of molecular tumor board on clinical outcomes in patients with refractory solid tumors: a real-world study.

Journal: The oncologist

Published: April 01, 2024

Impact of Molecular Tumor Board on Clinical Outcomes in Patients with Refractory Solid Tumor: a Real-World Study.

Impact of Molecular Tumor Board on Clinical Outcomes in Patients with Refractory Solid Tumor: a Real-World Study.

Journal: The oncologist

Published: April 01, 2024

Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy.

Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy.

Journal: Journal for immunotherapy of cancer

Published: March 25, 2024

New clinical trial design in precision medicine: discovery, development and direction.

New clinical trial design in precision medicine: discovery, development and direction.

Journal: Signal transduction and targeted therapy

Published: November 30, 2023

Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation.

Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation.

Journal: Nature communications

Published: October 24, 2023

Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.

Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.

Journal: Anti-cancer drugs

Published: February 02, 2023

Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.

Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.

Journal: International journal of cancer

Published: January 19, 2023

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy.

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy.

Journal: Frontiers in oncology

Published: July 30, 2022

Showing 1-12 of 41

Last Updated: 09/26/2026